TRIM7 and neoplasm: TRIM7 has also been reported as an agonist of TLR4-mediated signaling in macrophages [22], a tumour suppressor through degradation of Src [23], an oncogene through the K63-ubiquitination and stabilization of AP-1 co-activator RACO-1 [24] and an interactor and regulator of glycogenin—the latter activity giving rise to TRIM7s original designation as ‘glycogenin-interacting protein’ (GNIP) [25].